These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 4017414)
1. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin. Roy SD; Hawes EM; McKay G; Korchinski ED; Midha KK Clin Pharmacol Ther; 1985 Aug; 38(2):128-33. PubMed ID: 4017414 [TBL] [Abstract][Full Text] [Related]
2. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes. Roy SD; Hawes EM; McKay G; Hubbard JW; Midha KK Can J Physiol Pharmacol; 1985 Jul; 63(7):778-81. PubMed ID: 3876145 [TBL] [Abstract][Full Text] [Related]
3. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289 [TBL] [Abstract][Full Text] [Related]
4. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Woosley RL; Roden DM; Dai GH; Wang T; Altenbern D; Oates J; Wilkinson GR Clin Pharmacol Ther; 1986 Mar; 39(3):282-7. PubMed ID: 3081292 [TBL] [Abstract][Full Text] [Related]
5. The influence of pregnancy on the biotransformation and urinary excretion of methoxyphenamine in mice. Foster BC; Wilson DL; Cyr TD; Moffatt J; Buttar HS Biopharm Drug Dispos; 1995 Jan; 16(1):1-11. PubMed ID: 7711279 [TBL] [Abstract][Full Text] [Related]
6. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism. Roy SD; Hawes EM; Hubbard JW; McKay G; Midha KK Lancet; 1984 Dec; 2(8416):1393. PubMed ID: 6150386 [No Abstract] [Full Text] [Related]
7. Influence of urinary pH on the disposition of methoxyphenamine and three metabolites in humans. Roy SD; Hawes EM; Midha KK J Pharm Sci; 1987 Jun; 76(6):427-32. PubMed ID: 3625484 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin. McGourty JC; Silas JH; Fleming JJ; McBurney A; Ward JW Clin Pharmacol Ther; 1985 Oct; 38(4):409-13. PubMed ID: 2864157 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. Caraco Y; Sheller J; Wood AJ J Pharmacol Exp Ther; 1997 Apr; 281(1):330-6. PubMed ID: 9103514 [TBL] [Abstract][Full Text] [Related]
10. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523 [TBL] [Abstract][Full Text] [Related]
14. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio. Kallio J; Lindberg R; Huupponen R; Iisalo E Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585 [TBL] [Abstract][Full Text] [Related]
15. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Muralidharan G; Hawes EM; McKay G; Korchinski ED; Midha KK Eur J Clin Pharmacol; 1991; 41(5):471-4. PubMed ID: 1761076 [TBL] [Abstract][Full Text] [Related]
16. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Sloan TP; Idle JR; Smith RL Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615 [TBL] [Abstract][Full Text] [Related]
17. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Gross AS; Phillips AC; Rieutord A; Shenfield GM Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977 [TBL] [Abstract][Full Text] [Related]